Gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate hydrate (1:1:1)(CAS: 122795-43-1)

This compound must comply with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH regulations for European manufacturers and importers, and FDA/EPA guidelines for its use in medical imaging. Specific regulations may include hazard communication, storage, and disposal requirements.

Alternatives include other chelating agents like ethylenediaminetetraacetic acid (EDTA) or diethylenetriaminepentaacetic acid (DTPA). However, these may have different stabilities or binding affinities, and may not be as effective in certain applications.

Research trends focus on its use in medical imaging due to its gadolinium content. Market trends indicate a steady demand, driven by the need for contrast agents in MRI. Emerging research explores its use in targeted drug delivery systems and as a potential diagnostic tool in neurology.

This waste should be collected in appropriate containers, labeled as hazardous, and disposed of through a professional waste management service. Incineration or chemical treatment may be necessary for complete breakdown before disposal. Environmental protection and safety measures must be strictly followed to prevent contamination.